Review the side-effects of Albuterol and Ipratropium as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In ...

Active ingredients of dual-action Combivent® (ipratropium bromide and albuterol sulfate) Inhalation Aerosol now delivered by new propellant-free inhaler RIDGEFIELD, Conn., Oct. 10, 2011 /PRNewswire/ - ...

Albuterol or salbutamol and Ipratropium combination is prescribed to prevent wheezing, difficulty in breathing, chest tightness, and coughing in chronic obstructive pulmonary disease (COPD) such as ...

October 7, 2011 — The US Food and Drug Administration (FDA) has granted approval for an ipratropium bromide and albuterol sulfate inhalation spray (Combivent Respimat Inhalation Spray, Boehringer ...

Ipratropium albuterol cost per vial — fast shipping. It contains 2 bronchodilators ipratropium and albuterol, which relax the muscles in your lungs to open up the airways and make breathing easier ...

Ipratropium bromide 0.5 mg/3 mL (0.017%), albuterol (as sulfate) 2.5 mg/3 mL (0.083%); soln for inh. Not for primary treatment of acute attack. Avoid excessive use. Discontinue if paradoxical ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Todd A. Florin, MD ...

Albuterol is a fast-acting medication that's typically used in emergency situations to treat asthma in children. (Photo: Getty Images) Albuterol, a fast-acting medication used to treat breathing ...

RIDGEFIELD, Conn., April 13 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced that the U.S. Food and Drug Administration (FDA) has determined that the "essential use" ...

San Diego, Calif., May 19, 2009 – Data from two presentations highlighting the use of Perforomist® (formoterol fumarate) Inhalation Solution in moderate to severe chronic obstructive pulmonary disease ...

SILVER SPRING, Md. — The Food and Drug Administration plans to complete its phase out of inhalers that contain ozone-depleting chlorofluorocarbons by the end of the year, the agency said Wednesday.

COMBIVENT MDI and COMBIVENT RESPIMAT are the only short-acting bronchodilator products that offer two different medicines in a single inhaler. Clinical studies in patients with COPD have shown that ...